EyePoint Pharma Shuffles Execs and Board
Ticker: EYPT · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $45,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-appointments, employment-agreement
TL;DR
EyePoint Pharma brings in new CMO, adds two directors, and inks new CEO deal.
AI Summary
EyePoint Pharmaceuticals, Inc. announced on January 8, 2025, several key executive and board changes. The company appointed Dr. Marc O. Spiegel as Chief Medical Officer and elected Dr. Peter S. Arduini and Ms. Susan L. Levinson to its Board of Directors. Additionally, the company entered into a new employment agreement with its Chief Executive Officer, Dr. Yiannis Monioudis, effective January 8, 2025.
Why It Matters
These changes in leadership and board composition can signal strategic shifts or a renewed focus on specific areas of the company's operations and growth.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- Dr. Marc O. Spiegel (person) — Appointed Chief Medical Officer
- Dr. Peter S. Arduini (person) — Elected to Board of Directors
- Ms. Susan L. Levinson (person) — Elected to Board of Directors
- Dr. Yiannis Monioudis (person) — Chief Executive Officer
- January 08, 2025 (date) — Effective date of changes
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Marc O. Spiegel has been appointed as the new Chief Medical Officer.
Who were elected to the Board of Directors?
Dr. Peter S. Arduini and Ms. Susan L. Levinson were elected to the Board of Directors.
What is the effective date of the reported events?
The earliest event reported is effective January 08, 2025.
Has the CEO's employment agreement been updated?
Yes, the company entered into a new employment agreement with its Chief Executive Officer, Dr. Yiannis Monioudis.
What was EyePoint Pharmaceuticals' former company name?
EyePoint Pharmaceuticals, Inc. was formerly known as pSivida Corp. and pSivida LTD.
Filing Stats: 806 words · 3 min read · ~3 pages · Grade level 10 · Accepted 2025-01-08 07:05:08
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind
- $45,000 — will receive an annual cash retainer of $45,000 for his Board service for 2025. Dr. San
Filing Documents
- eypt-20250108.htm (8-K) — 45KB
- eypt-ex99_1.htm (EX-99.1) — 24KB
- img96707757_0.jpg (GRAPHIC) — 97KB
- 0000950170-25-003280.txt ( ) — 314KB
- eypt-20250108.xsd (EX-101.SCH) — 23KB
- eypt-20250108_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On January 8, 2025, the Company issued a press release announcing the appointment of Dr. Sanders to the Board. A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint Pharmaceuticals, Inc. dated January 8, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: January 8, 2025 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer